HGH Fragment 176-191.
About HGH Fragment 176-191
HGH Fragment 176-191 is among the compounds studied in metabolic and weight-regulation research. Mimics the lipolytic C-terminal domain of growth hormone without acting through the GH receptor; stimulates lipolysis via beta-adrenergic signaling, without the insulin-antagonizing effects of full-length GH.
Research Application
Studied in animal models as a lipolytically active, non-diabetogenic fragment. However, the practically usable efficacy/safety data almost entirely derive from AOD9604 studies rather than the unmodified fragment itself.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
A growing number of preclinical and clinical studies exist for metabolic peptides, though the volume varies significantly by substance.
- Heffernan M, et al. Endocrinology. 2001;142(12):5182–5189. PMID 11713213
- Ng FM, et al. Horm Res. 2000;53(6):274–278. PMID 11146367
- Cox HD, et al. Drug Test Anal. 2015;7(1):31–38. PMID 25208511
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Similar Peptides
Question about HGH Fragment 176-191?
We reply personally – via email or Telegram.